Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Continue advancement of MRT-6160 through Phase 2 initiation, in collaboration with Novartis. Share additional MRT-2359 Phase 1/2 study data in ...